Singapore, Jan. 16 -- A2A Pharmaceuticals Inc. (A2A) announced an agreement to design and co-develop oncology drug candidates with Daewoong Pharmaceutical Co., Ltd. (Daewoong), a major pharmaceutical company in South Korea, using its proprietary AI-enabled drug discovery platform SCULPT. The companies will collaborate on up to three oncology drug targets to accelerate Daewoong's efforts to develop innovative oncology treatments through open collaboration.

Under this collaboration, A2A will use its computational drug discovery platform to design new compound structures, which will be synthesized and evaluated by Daewoong. Both parties will actively cooperate in preclinical optimization and selection of lead candidates to enter the clinic....